西格列汀与吡格列酮分别联用二甲双胍治疗肥胖型2型糖尿病的成本－效果研究

摘要

Objective To explore the cost-effectiveness of sitagliptin and pioglitazone respectively combined with metform-in in treatment of obese type 2 diabetic mellitus (T2DM).Methods 60 cases of T2DM administered with metformin were random-ized into the sitagliptin group (n=30)and the pioglitazone group (n=30), which were treated with sitagliptin and pioglitazone re-spectively.Data including medical expenses, glycosylated hemoglobin A1c, fasting and postprandial blood glucose levels, the number of cases of hypoglycemia, BMI in the two groups before and after 12 weeks of the treatment were analyzed and compared between the two groups.Results After 12 weeks of the treatment, there was no significant difference in glycosylated hemoglobin A1c, fasting and postprandial blood glucose levels between the two groups.No hypoglycemia occurred in the two groups.But there was significant difference in BMI and cost-effectiveness of medical expenses between the two groups.Conclusion The cost-effectiveness of sita-gliptin with metformin in treatment of T2DM is superior to that of pioglitazone with metformin in treatment of T2DM.%目的：比较西格列汀与吡格列酮分别联用二甲双胍治疗肥胖型2型糖尿病的成本－效果对比。方法60例2型糖尿病肥胖患者在服用二甲双胍片的前提下，随机分为西格列汀组（n＝30）和吡格列酮组（n＝30），分别给以西格列汀片与吡格列酮片口服，检测入组时和治疗12周后两组医疗费用、糖化血红蛋白、空腹及餐后血糖水平、低血糖例数、体重指数等数据。结果治疗12周后，西格列汀组患者的糖化血红蛋白、空腹及餐后血糖水平与吡格列酮组比较无统计学差别，两组均无低血糖的发生，但在体重指数和医疗费用产生的成本－效果有统计学差异。结论西格列片汀联用二甲双胍片治疗肥胖型2型糖尿病的成本－效果优于吡格列酮片联用二甲双胍片。